---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-26-000097"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2026-08-05T10:31:36+00:00"
generated_at: "2026-08-05T10:35:51.729472+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Recursion Pharmaceuticals Reports Q2 2026 Results; Genentech Options First Neuroscience Target

## Summary
- Genentech exercised first Validated Target Option under neuroscience collaboration, advancing a previously unexplored target into early discovery program.
- REC-4881 Phase 2 FAP data to be presented at CGA-IGC Presidential Plenary in November 2026; FDA discussions initiated for registrational path.
- REC-7735 IND cleared; Phase 1/2 ZINNIA trial for PIK3CA H1047R-mutant solid tumors to start in 2H26.
- Revenue was $7.7M in Q2 2026, down from $19.2M in Q2 2025; net loss improved to $131.0M from $171.9M.
- Cash operating expense guidance reduced to <$375M for 2026; cash runway extends into early 2028.

## SEC filing metadata
- accession: 0001601830-26-000097
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2026-08-05T10:31:36+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000097/0001601830-26-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183026000097/rxrx-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-26-000097
- JSON: https://secwatch.observer/filing/0001601830-26-000097.json
- Plain text: https://secwatch.observer/filing/0001601830-26-000097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.